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Verne patients with chronic heart failure in the absence of 
atrial fibrillation. For a long time, the safety of digitalis was 
n source of concern. We now know that digitalis toxicity can 
be awide in most oatients with chronic heart failure and is 
not an important diwback to the use of this agent. These 
issues are no longer sources of controversy: in fact. there is 
little doubr that digitalis should be used in the treatment of 
chmnic heart failure. We do not know. however. when 
therapy with digitalis should be utilized. This new contrc- 
versy will likely continue for many years. as new phamxa- 
cologic interventions are developed and become accepted as 
effective therapeutic modalities and thus challen~c the 
choice of digitalis as a tint line agent after diuretics in the 
~reaunent of ratients with symptomatic left ventricular dys- 
function. 
How rhmrld we decide whelher digiro!is or 0 new *her”- 
perrric nppronch (such OS vasodiloror therapy) should be 
used a/.~ diuretics in chronic heart JX”re? We need to 
compare the effects ofthese two phamtacologic strategies on 
the three primary goals of treatment of these severely ill 
oatients: relief of sym~ltorns of hean failure. increase in 
exercise tolerance and &ongation of life. It is impartant o 
note that an increase in cardiac output or in left ventricular 
ejection fraction should not be considered to be one of the 
major goals of therapy in patients with symptomatic left 
ventricular dysfunction because changes in these variables 
do not parallel changes in symptoms or exercise capacity (Il. 
Which of the treatment options now available (digitalis or 
vascdilator drugs) provides the m”st consLstcnt benefits on 
symptotm and survival in patients with chmnic hean fail- 
ure? 
Effects of digitals and vasodiIators MI syt”pto”!S. Al- 
though digitalis can impmve left ventricular pafmmance in 
many patients with chmnic heart failure, the results of 
do”ble.blind, &&c-controllrd studies have raised cat- 
cents that thebe hemcdynamic effects may not be consis- 
tently translated inlo clinical benefits. Fleg et al. (2) noted 
that the withdrawal of digitalis from patients with chronic 
heart failure and normal sinus rhythm was accompanied by a 
small but significant increase in left ventricular end-diastolic 
dimension and circumferential shortening. but these adverse 
hemodvnamic chances were not accomwttied by any dete- 
rioratidn in sympt&ns or exercise ca&ty. The lack of 
clinical deterioration after the withdrawal of digitalis was 
The mle of digitalis in the management of congestive heati 
failure has been the center of controversy for m”re than 200 
years. but the focus of thin debate has changed substantially 
during the wurse ofclinical investigations with the drug. For 
a long time, the efficacy of digitalis in the treatment of 
congestive heart failure in patients with nomxal sinus rhythm 
was in doubt. We n”w know that digitalis can be effective in tricular ejection fraction at peak exercise, but these hem”- 
contimted in another double-blind, placebo-cordmlled trial 
by Gheorghiade t al. (3). who noted no significant changes 
in symptoms. ien ventricular ejection fraction or exercise 
duration in patients with chmnic heart failure in whom 
digitalis was withdrawn for I month. In a third. recently 
completed. double-blind crossover sludy of digoxin in pa- 
tients with chronic heart failure due to ischemic hearI 
disease, Fleg et al. (4) found that digitalis pmdtlced a 
significant increase in systolic blood pressure and lefl ven- 
dvnamic e5zcts were not accamoanied bv an im!xovement itv, althawh the differences noted between captopril- and 
in exercise capacity. Although the favor~blc he&dynamic 
response to digitalis in these studies indicated that the 
positive inotropic effects of digitalis were sustained during 
long-term treatment, these pharmacologic benefits did not 
necessarily lead to an improvement in symptoms or well- 
being. These three studies indicate fhatdigitalisprovidesfew 
therapeutic advantages in most ambulatory patients with 
compensated congestive heart failure and normal sinus 
rhythm. 
Thrse &i!o slmdd nol he inrerprercd ro s~~~~PsI. bow- 
cwr. r/m di,&a/is is inefcrdvr in o/l poriem wirh rlrrowc 
heurt fnihw. Several controlled studies show that some 
patients with heart failure show hemodynamic and sympto- 
matic improvement aher digitalis therapy. but this benefit is 
largely seen in patients with the most advanced disease, 
assessed by either hemodynamic or clinical variables. Digi- 
talis pmduces the most improvement in cardiac performance 
and in functional capacity in patients with the most marked 
lefl ventricular dilation, the lowest values fur left venticular 
ejection fraction and the most severely compromised excr- 
cise capacity (2-S). This concept was recently supported by 
Gheorghiade et al. (9). who evaluated the hemodynamic 
effects of digoxin in patients with heart failure who were 
being treated only with diuretics and vasodilators on their 
initial presentation to the physician. Rtients who responded 
favorably to digitalis had more advanced cardiac dysfunction 
(as reflected by a lower cardiac index and a higher pulmo- 
nary wedge pressure) than did patients who did not respond 
to the drug. These investigators suggested that digitalis 
should be used primarily in patients with severe chmnic 
hean failure who remain hemodynamically or clinically 
decompensated after optimal therapy with diuretics and 
vasodilators. There would appear to be little reason to 
administer digitalis to patients with congestive heart failure 
who have only mild to moderate symptoms. 
How &a/d UT Ihen ITPUI pokwrs err/y in rbeir discox 
procc~s wlwr rlwy how only u mild IO modcrm linrirorio~~ of 
e.wrcbe crrporily? The recently completed multicenter com- 
parison of captopril and digoxin (IO) in patients with mild to 
moderate heart failure provides important information thal 
may help us answer this question. In that study, 300 patients 
with mild to moderate wn~tcm despite treatment with 
diuretics were randomly ads&cd (in a double-blind fashion1 
to additional therapy with digoxin. captopril or placebo for 6 
months. During the course of the study, bothbigoxin- and 
captopril-treated patients had significantly fewer hospitaliza- 
tions and visits to the emergency room for the treatment of 
decompensated heart failure than did patients treated with 
placebo despite a marked increase in the need for additional 
diuretics in the placebo-treated group. When compared with 
patients receiving placebo. only patients treated with capto- 
pril (but not those treated with digoxin) showed a significant 
improvement in exercise tolerance and in functional capac- 
digoxin-t&ted patients were not significant. Although only 
digoxin-treated patients showed a significant increase in leh 
ventricular ejection fraction (when compared with both 
captopril- and placebo-treated patients). this hemodynamic 
imorovemenr did not aooear to be translated into imwtant 
clinical benefits. The risk of active treatment in these pa 
tients with mild to moderate heart failure was minimal. Both 
captopril- and dig&-treated patients experienced fewer 
adverse reactions than did patients treated with placebo 
because of the high frequency of worsening heart failure in 
placebo-treated patients. Although some padents treated 
with captopril experienced transient dizziness and minm 
increases in serum creatinine and potassium, these events 
did nor require the discontinuation of therapy or the with- 
drawal of patients from the study. 
In their review of all available placebo-controlled. dou- 
ble-blind. randomized trials of therapeutic agents in the 
treatment of chronic congestive heart failure. Dollcry and 
Corr (I I) concluded that the benefits of digitalis in patients 
treated with diuretics had not been established. In contrast. 
in their opinion. numcmus well controlled studies showed 
that hemodynamic nad symptomatic benefits consistently 
followed the use of converting enzyme inhibitors in these 
patients. The results of the placebo-controlled multicenter 
comparison of captopril and digoxin (IO) (previously cited) 
extend these conclusions to patients with mild compensated 
congestive hean failure. 
Effect 01 digitalis and vasodilators on survival. Many 
investigators (12.13) have raised concerns that digitalis may 
exert a deleterious effect on the survival of patients with 
chronic congestive heart failure, especially in those with 
ischemic heart disease. In a retrospective analysis of indi- 
viduals followed up after an acute myocardial infarction. 
patients treated with digitalis had a higher mortality rate than 
did those who did not receive the drug. This difference in 
mortality was in part attributable to the greater prevalence of 
congestive heart failure in digitalis-treated patients, hut an 
association ofdigitalis and increased mortality was apparent 
even when attempts were made to correct for all known 
imbalances between the treatment groups. None of there 
analyses could rule out with confidence a potential adverse 
effect of digitalis on survival. These observations have 
underscored concerns that digitalis may enhance the risk of 
serious ventricular arrhythmias (and the risk of sudden 
dealh) in patients with congestive heart failure. even in the 
absence of clinically apparent toxicity. Allhough the only 
reliable melhod to evaluate the effect ofdigitalis on mortality 
is by the conduct of a large randomized study (14). the 
available data do not suggest a major he~wficicrl effect of this 
drug an survival. 
shown to prolong life in patients with chronic heart failure. 
The Veterans Administration Vasodilator Heart Failure 
Trial (V-HEFT) (15) demonstrated that a combination of 
isosorbide dinitrate and hydraiazine WBS effective in reduc- 
ing mortality in patients with moderate to severe chronic 
heart failure. Two trials (16.17) with the converting enzyme 
inhibitors captopril and enalapril have shown thl inhibition 
of the renin-angiotension system can prolong life in severely 
symptomatic patients. In contrast to digitalis, convening 
enzyme inhibitors reduce the frequency and complexity of 
ventricular arrhythmias in patients with mild, moderate and 
severe congestive heart failure (10,18.19). and may reduce 
the frequency ofsudden death (17). Additional dala kern- 
ing the effect of converting enzyme innibitors on survival in 
less severely ill patients should be available in the next 
several years fmm a number of lame scale multicenter trials: 
Studies-of Left Ventricular Dynknction (SOLVD). span- 
sored by the National Heart. Lung. and Blood Institute: the 
use of converting enzyme inhibitors soon after an acute 
myocardial infarction (Survival and Ventricular Enlame- 
r&t, SAVE) and a comparison of the effect of convertkg 
enzyme inhibitors and direct-actinp vasodilators on surviva! 
(V-keFT II). sponsored by the Veterans Administration. 
Condusions. The observations cited in this edirorial re- 
view strongly suggest hat digonin should not be the drug of 
first choice after diuretics in most patients with chronic 
congestive heart failure. In view “i me equivocal and vati- 
able effectr. of dig&n on symptoms and exercise tolerance 
in the patialt with compensated heart failure. in view of the 
consistent bewtits of convertingenzyme inhibitors on symp 
kxns and exercise capacity in all grades of hem failure and 
in view of growing evidence that vasodilaton (particularly. 
the convening enzyme inhibitors) can improve survival. I 
prefer to treat patients with chronic heart failure and normal 
sinus rhythm with a diuretic and a converting enzyme 
inhibitor. Digitalis appears to be most e&rive in patients 
with severe chmnic heart failure and should be added when 
symptoms persist despite optimal treatment with a diuretic 
and a converting enzyme inhibitor or in patients who cannot 
tolerate vasodilator therapy. 
